Nanjing Bioheng Biotech Co., Ltd.
Clinical trials sponsored by Nanjing Bioheng Biotech Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immune reset: CAR-T cells take on lupus and more Results expected Dec 2026 (estimated)
- Immune reset: CAR-T therapy targets lupus, MS, and more Results expected Jan 2027 (estimated)
- Experimental CAR-T therapy takes on lupus and more Results expected Jul 2027 (estimated)
-
Could CAR-T cells tame autoimmune diseases? early trial begins
Disease control PausedThis early-phase trial is testing a CAR-T cell therapy called RD06-04 in 12 people with active autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves reprogramming a patient's own immune cells to target and destroy faulty B cells. The main goal is to …
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Immune cell therapy aimed at autoimmune diseases hits early snag
Disease control CancelledThis early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC